Glucophage AEs Not Comparable To Rezulin Liver Deaths - FDA Consultant
Executive Summary
The risk of lactic acidosis associated with Bristol-Myers Squibb's Glucophage should not be compared to liver toxicities associated with Rezulin because the Glucophage side effects can be more easily managed through education, FDA consultant Saul Genuth, MD, Case Western Reserve University, told FDA's Endocrinologic & Metabolic Drugs Advisory Committee.